S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
CAMBRIDGE, MA—In recent transactions disclosed through an SEC Form 4 filing, Verve Therapeutics , Inc. (NASDAQ:VERV) CEO Sekar Kathiresan reported the sale of 9,822 shares of common stock, valued at approximately $40,761. The shares were sold at a price of $4.15 each on April 2, 2025, amid a challenging period for the stock, which has declined 26% in the past week and is trading near its 52-week low of $3.77. This sale was part of a pre-established plan to cover tax liabilities from vested restricted stock units (RSUs) and was not a discretionary trade by Kathiresan.
On the previous day, April 1, Kathiresan acquired 33,000 shares through the conversion of RSUs, which were settled on their scheduled vesting date. This transaction did not involve any cash exchange, as the restricted stock units convert into common stock on a one-for-one basis. Following these transactions, Kathiresan holds 356,508 shares directly and additional shares indirectly through family trusts.
Verve Therapeutics, headquartered in Boston, focuses on developing transformative therapies for cardiovascular diseases. The company’s stock is traded on the NASDAQ under the ticker VERV. InvestingPro analysis suggests the stock is currently undervalued, with analyst price targets ranging from $15 to $32. For deeper insights into VERV’s valuation and 13 additional ProTips, including detailed financial analysis, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Verve Therapeutics has received clearance from the FDA for its Investigational New Drug (IND) application for VERVE-102, a gene-editing drug aimed at treating cardiovascular diseases like heterozygous familial hypercholesterolemia and premature coronary artery disease. This milestone allows the company to proceed with its Phase 1b clinical trial in the U.S., following successful interim data from international sites showing no treatment-related serious adverse events. Analysts from BMO Capital Markets and Canaccord Genuity have maintained positive outlooks on Verve Therapeutics, with BMO setting a price target of $30 and Canaccord at $32. Both firms anticipate promising results from the upcoming second-quarter data readout, which could further validate the drug’s efficacy. H.C. Wainwright also raised its price target for Verve to $15, expressing optimism due to the previous success of VERVE-101 in reducing LDL cholesterol levels. The developments are closely watched by investors, as Verve’s innovative approach aims to offer long-term cholesterol reduction after a single treatment. Meanwhile, the broader biotech sector is experiencing turbulence following the resignation of FDA’s top vaccine official, Peter Marks, which has raised concerns about potential changes in regulatory approaches. This shakeup has led to declines in shares of several biotech companies, highlighting the industry’s reliance on a stable regulatory environment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.